← All stocks

Traws Pharma, Inc.

TRAW Net buying
CIK 0001130598 #5313 in the set updated 18 Sep 2026
Bought (12 mo)
$998.21K
out of their own pocket, the only kind of buying there is
Sold (12 mo)
$0.00
$0.00 on a plan · $0.00 straight out of an exercise
Sold at will
$0.00
0 of 0 sales
Net
+$998.21K
+$998.21K against sales at will

By person

12 insiders · 1 transaction
Insider
Role
Bought
Sold
Net
Holding
Worth
Change
ORBIMED ADVISORS LLC entity
10% owner
$998.21K (1)
+$998.21K
1,203,250
$2.01M
+98.7%
Dukes Iain D.
Chief Executive Officer
171,130
$285.79K
+27.5%
Savchuk Nikolay
Chief Operating Officer
150,606
$251.51K
+12.2%
Pauza Charles David
Chief Science Officer Virology
115,971
$193.67K
+18.9%
Redfield Robert
Chief Medical Officer
113,919
$190.24K
+16.8%
CAUTREELS WERNER
Director
109,222
$182.40K
+1,265%
Parker Charles Nolan
Chief Financial Officer
15,393
$25.71K
Shoemaker Mary Teresa
Director
6,292
$10.51K
+4,561%
STOVER JACK E
Director
6,165
$10.30K
+76,963%
Clarke Trafford
Director
6,157
$10.28K
Leaman John Harold
Director
4,058
$6.78K
TPAV, LLC entity
10% owner
0
$0.00
−100.0%

No percentages here. This company's share count has moved by a factor of 5.1 over the window, from 3,025,554 to 15,368,277 shares. A split, a merger or a large issue changes what the company is, and a holding measured at one point in that run is not a fraction of it at another.

Nothing of that kind in this period.

What was left out

Form 4 filings counted 40
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 1
Sales on a Rule 10b5-1 plan 0
Sales straight out of an exercise 0
Sales at will 0
Transactions with no price 0
Shares from compensation/vesting 131,048
History held since 1 Sep 2016